What is Ischemix?
Ischemix, Inc. operates at the intersection of biotechnology and neuro-pharmacology, focusing on the development of novel cytoprotective compounds. The company's primary asset, CMX-2043, represents a significant innovation in the treatment of traumatic brain injury (TBI). By leveraging multi-modal activity, the compound aims to mitigate cellular damage in high-acuity clinical settings. The firm maintains a robust intellectual property portfolio, with global patents covering both the composition and therapeutic application of its lead candidate, positioning it as a key player in the development of neuro-protective therapies.
How much funding has Ischemix raised?
Ischemix has raised a total of $6.6M across 1 funding round:
Private Equity
$6.6M
Private Equity (2013): $6.6M with participation from Norris Capital
Key Investors in Ischemix
Norris Capital
Norris Capital Group is a financial firm led by Wayne O. Norris, specializing in business plan modeling, balance sheet re-engineering, and facilitating significant mezzanine and equity raises for growth-oriented enterprises.
What's next for Ischemix?
Following this major enterprise-level funding, Ischemix is expected to prioritize the advancement of CMX-2043 through the rigorous stages of preclinical and clinical development. The strategic allocation of this capital will likely focus on expanding the therapeutic scope of its lead candidate and strengthening its regulatory pathway. As the company transitions into more intensive research phases, the focus will remain on validating the efficacy of its cytoprotective platform to address the unmet needs of patients suffering from complex TBI, ultimately aiming to translate preclinical success into viable, market-ready medical solutions.
See full Ischemix company page
